With its first drug approval and the first approved therapy for the ultra-rare immunodeficiency disorder WHIM syndrome, X4 Pharmaceuticals, Inc. told a 29 April investor call that while Xolremdi (mavorixafor) will be available immediately, it sees 2024 as a year for laying the groundwork for clinician understanding and payer acceptance of the drug.
Key Takeaways
-
About two years after a 20% staff cut, X4 gets its first FDA approval for Xolremdi in the rare immunodeficiency disorder WHIM syndrome.
-
The...
Xolremdi is a once-daily capsule indicated in the US as a 400mg dose in patients weighing more than 50kg and dosed at 300mg in patients at or below 50kg. It...